During the 5th Global NASH Congress in London, Our Chief Scientific Officer Prof. Dr. D.E. Grobbee was one of the speakers and presented: Getting GRIP on NASH; Implementation of an International Clinical Screening Program. During this presentat...
In this webinar, Prof. Jörn Schattenberg discussed his paper in Nature Reviews Gastroenterology & Hepatology on effective and efficient models of care for patients with NAFLD. Standardized patient care pathways for NAFLD are not yet widely im...
Topics that has been discussed: The Impact of NAFLD/NASH What is being done to tackle NAFLD/NASH globally and nationally What still needs to be done in the fight against NAFLD/NASH How can you/your country advance the battle against ...
Genome-wide association studies have uncovered robust and reproducible associations between several genetic variations and the natural history of NAFLD. During this webinar, Professor Eric Trépo reviewed these findings that have provided compelli...
During this webinar Prof. Sven Francque discussed the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (p...
This webinar focussed on the close multilevel links between insulin resistance/T2DM and NAFLD. Topics that are discussed: Epidemiological links between NAFLD, insulin resistance and T2DM Insulin resistance as root cause of NAFLD: mechan...
Given the high prevalence of NAFLD in the general population, identifying the persons at a high risk for development of cirrhosis is key. During this presentation, Professor Hannes Hagström focussed on methods and strategies to achieve this in di...
Curious about the challanges in NASH clinical trials? And how to overcome them? Watch the NASH Clinical webinar: What are the challenges in NASH clinical trials? And how to overcome them?
Personalization is the new king of global outsourcing. Patients are crying out for more flexible, more diverse and less burdensome trial designs, while the ever larger CROs become less versatile with every merger. It’s no surprise that pharma is...
"*" indicates required fields
"*" indicates required fields
